Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy

Rutika A. Kokate, Pankaj Chaudhary, Xiangle Sun, Sanjay I. Thamake, Sayantan Maji, Rahul Chib, Jamboor K. Vishwanatha, Harlan P. Jones

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. Materials & methods: Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. Results: CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. Conclusion: Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.

Original languageEnglish
Pages (from-to)479-494
Number of pages16
JournalNanomedicine
Volume11
Issue number5
DOIs
StatePublished - Mar 2016

Fingerprint

Nanoparticles
Dendritic Cells
tumor
antigen
Acids
Tumors
acid
Neoplasm Antigens
Antigens
induction
activation
cancer
Therapeutics
polylactic acid-polyglycolic acid copolymer
Milk
nanoparticle
therapy
bone
Bone
Bone Marrow

Keywords

  • DCs
  • NP
  • breast cancer
  • cancer vaccines
  • dendritic cells
  • immunotherapy
  • nanoparticle

Cite this

@article{5dcdc76bcc544a45a8a2e283e2e34b97,
title = "Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy",
abstract = "Background: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. Materials & methods: Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. Results: CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. Conclusion: Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.",
keywords = "DCs, NP, breast cancer, cancer vaccines, dendritic cells, immunotherapy, nanoparticle",
author = "Kokate, {Rutika A.} and Pankaj Chaudhary and Xiangle Sun and Thamake, {Sanjay I.} and Sayantan Maji and Rahul Chib and Vishwanatha, {Jamboor K.} and Jones, {Harlan P.}",
year = "2016",
month = "3",
doi = "10.2217/nnm.15.213",
language = "English",
volume = "11",
pages = "479--494",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "5",

}

Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. / Kokate, Rutika A.; Chaudhary, Pankaj; Sun, Xiangle; Thamake, Sanjay I.; Maji, Sayantan; Chib, Rahul; Vishwanatha, Jamboor K.; Jones, Harlan P.

In: Nanomedicine, Vol. 11, No. 5, 03.2016, p. 479-494.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy

AU - Kokate, Rutika A.

AU - Chaudhary, Pankaj

AU - Sun, Xiangle

AU - Thamake, Sanjay I.

AU - Maji, Sayantan

AU - Chib, Rahul

AU - Vishwanatha, Jamboor K.

AU - Jones, Harlan P.

PY - 2016/3

Y1 - 2016/3

N2 - Background: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. Materials & methods: Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. Results: CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. Conclusion: Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.

AB - Background: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. Materials & methods: Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. Results: CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. Conclusion: Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.

KW - DCs

KW - NP

KW - breast cancer

KW - cancer vaccines

KW - dendritic cells

KW - immunotherapy

KW - nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=84962578587&partnerID=8YFLogxK

U2 - 10.2217/nnm.15.213

DO - 10.2217/nnm.15.213

M3 - Article

C2 - 26892440

AN - SCOPUS:84962578587

VL - 11

SP - 479

EP - 494

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 5

ER -